These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 27621608

  • 1. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [Abstract] [Full Text] [Related]

  • 4. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 5. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.
    Respir Res; 2016 Jun 18; 17(1):73. PubMed ID: 27316465
    [Abstract] [Full Text] [Related]

  • 6. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 18; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 7. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 18; 12():3329-3339. PubMed ID: 29200840
    [Abstract] [Full Text] [Related]

  • 8. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.
    Int J Chron Obstruct Pulmon Dis; 2014 Jun 18; 9():697-714. PubMed ID: 25045258
    [Abstract] [Full Text] [Related]

  • 9. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 18; 14():181-194. PubMed ID: 30655665
    [Abstract] [Full Text] [Related]

  • 10. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L.
    Respir Med; 2015 Oct 18; 109(10):1312-9. PubMed ID: 26320402
    [Abstract] [Full Text] [Related]

  • 11. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
    Bai CX, Tang Y, Xin JB, Li YL, Li ZK, Kang J, Huang JA, Xiao W, Wen ZG, Fu XH, He B, Liu CT, Chen P.
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov 12; 42(11):838-844. PubMed ID: 31694094
    [Abstract] [Full Text] [Related]

  • 12. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting.
    Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 12; 14():1441-1453. PubMed ID: 31308649
    [Abstract] [Full Text] [Related]

  • 13. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.
    Respir Med; 2017 Jan 12; 122():58-66. PubMed ID: 27993292
    [Abstract] [Full Text] [Related]

  • 14. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies.
    Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT.
    Adv Ther; 2020 Aug 12; 37(8):3485-3499. PubMed ID: 32462607
    [Abstract] [Full Text] [Related]

  • 15. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.
    Ther Adv Respir Dis; 2018 Aug 12; 12():1753465818755091. PubMed ID: 29439648
    [Abstract] [Full Text] [Related]

  • 16. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials.
    Rabe KF, Chalmers JD, Miravitlles M, Kocks JWH, Tsiligianni I, de la Hoz A, Xue W, Singh D, Ferguson GT, Wedzicha J.
    Adv Ther; 2021 Jan 12; 38(1):579-593. PubMed ID: 33175291
    [Abstract] [Full Text] [Related]

  • 17. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
    Saito T, Takeda A, Hashimoto K, Kobayashi A, Hayamizu T, Hagan GW.
    Int J Chron Obstruct Pulmon Dis; 2015 Jan 12; 10():2393-404. PubMed ID: 26604737
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E, Brusselle GG, Joos GF.
    Int J Chron Obstruct Pulmon Dis; 2016 Jan 12; 11():3163-3177. PubMed ID: 28008243
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT.
    Adv Ther; 2020 Oct 12; 37(10):4175-4189. PubMed ID: 32671684
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun 12; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.